Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat forms of the disease.

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

With the administration’s aggressive tactics, pharmaceutical companies cannot avoid this reckoning, but they can shape how it unfolds.

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.

AstraZeneca, a global biopharmaceutical company with ~$43 billion in 2022 revenues and nearly 90,000 employees (aiexpert.network) (blogs.microsoft.com), is rapidly integrating large language model (LLM)–based generative AI—including tools like ChatGPT—across its enterprise and R&D operations. The company has invested heavily (>$250 million) in AI research (emerj.com) (aiexpert.network) and embedded AI in data and processes, from ideating drug targets to streamlining clinical trials (Table below). By mid-2025, AstraZeneca had launched company-wide initiatives to upskill ~12,000 employees on generative AI, with 85–93% of surveyed staff reporting productivity gains from AI tools (www.astrazeneca.com) (www.clinicalresearchnewsonline.com). Notably, AstraZeneca pilots “AI assistants” for tasks like 3D CT-scan analysis and automated protocol drafting, achieving significant time savings for experts (www.clinicalresearchnewsonline.com) (www.clinicalresearchnewsonline.com). These efforts align top-down with AstraZeneca’s 2030 goals (20 new medicines, $80 billion revenue (www.clinicalresearchnewsonline.com) (www.klover.ai)) by accelerating discovery and development processes. Go to Source

AstraZeneca joins Trump’s drug pricing plan, pledging $50bn US investment and discounts of up to 80% to cut prescription medicine costs.

The company will sell some medicines at a discount to the government's Medicaid health plan in exchange for tariff relief.

The first stage of AstraZeneca's promised $50 billion investment in US facilities is underway as it breaks ground on a facility in Virginia.

AstraZeneca’s Bax24 Phase III trial demonstrates sustained blood pressure control and a favorable safety profile in patients with treatment-resistant hypertension.

AstraZeneca's baxdrostat has hit the mark in another phase 3 trial in resistant hypertension, keeping it on track for filings later this year.

The $264 bln pharma firm’s plan to list shares in the US shifts trading stateside and helps UK investors sidestep tax. Other US-focused groups like Experian and RELX could copy the move to boost liquidity. That will erode the City’s status and the UK’s dwindling coffers.

AstraZeneca has inked a deal worth “up to” $555 million with San-Francisco startup Algen Biotechnologies to mine new immunology targets using AI-guided CRISPR

AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment.

Today’s Respiratory Updates: AstraZeneca’s AIRSUPRA adds BATURA mild-asthma data to its US label, cutting severe exacerbations by 46 percent. United Therapeutics’ Tyvaso met the TETON-2 primary endpoint with FVC gains in IPF. Tezspire earned a CHMP nod for CRSwNP, slashing surgery need by 98 percent. Merck’s clesrovimab received a CHMP positive opinion for single-dose infant RSV prevention. Vapendavir showed clinical benefit in a COPD rhinovirus challenge. An omalizumab biosimilar BLA was filed, while zelasudil and deupirfenidone delivered encouraging IPF signals, with stabilization Phase 3 planning.

AstraZeneca’s Koselugo Gains EU Approval Recommendation for Adult Neurofibromatosis Treatment - MSN

Today’s Respiratory Updates: AstraZeneca’s AIRSUPRA adds BATURA mild-asthma data to its US label, cutting severe exacerbations by 46 percent. United Therapeutics’ Tyvaso met the TETON-2 primary endpoint with FVC gains in IPF. Tezspire earned a CHMP nod for CRSwNP, slashing surgery need by 98 percent. Merck’s clesrovimab received a CHMP positive opinion for single-dose infant RSV prevention. Vapendavir showed clinical benefit in a COPD rhinovirus challenge. An omalizumab biosimilar BLA was filed, while zelasudil and deupirfenidone delivered encouraging IPF signals, with stabilization Phase 3 planning.

AstraZeneca’s Koselugo Gains EU Approval Recommendation for Adult Neurofibromatosis Treatment - MSN

AstraZeneca’s Koselugo Gains EU Approval Recommendation for Adult Neurofibromatosis Treatment - MSN